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Insulin-like growth factors and cancer: no role in screening.
Evidence from the BUPA study and meta-analysis of prospective
epidemiological studies
JK Morris*,1, LM George1, T Wu1 and NJ Wald1
1Centre for Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Barts and The London Queen Mary’s School of Medicine
and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
Insulin-like growth factor-1 (IGF-1), insulin-like growth factor-2 (IGF-2), and insulin-like growth factor binding protein-3 (IGFBP-3)
were measured in frozen serum samples from 1051 men with cancer and 3142 controls in a nested case–control study from the
British United Provident Association (BUPA) study cohort and associations with 14 cancers were examined, including prostate,
colorectal, and lung. A meta-analysis of studies on these three cancer sites was also conducted. In the meta-analysis the odds ratio
between the highest quartile IGF-1 group and the lowest quartile group was 1.31 (95% confidence interval (CI): 1.03–1.67) for
prostate, 1.37 (1.05–1.78) for colorectal and 1.02 (0.80–1.31) for lung cancer, and for IGF-2 it was 0.72 (0.36–1.44) for prostate and
1.95 (1.26–3.00) for colorectal cancer. Results from the BUPA study were consistent with the estimates from the other studies.
There were no statistically significant associations with IGFBP-3 and any of the cancer sites considered. Our results suggest that IGF-1,
IGF-2, and IGFBP-3 measurements have no value in cancer screening, although IGF-1 and IGF-2 may be of aetiological significance in
relation to colorectal and prostate cancer.
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Prospective studies have shown that higher circulating concentra-
tions of insulin-like growth factor 1 (IGF-1), insulin-like growth
factor 2 (IGF-2), and insulin-like growth factor binding protein-3
(IGFBP-3) are associated with an increased risk of prostate cancer,
colorectal cancer, and premenopausal breast, and ovarian cancer
(Lukanova et al, 2002; Renehan et al, 2004). Aetiological
importance has been attributed to these associations, and it has
been suggested that they may be of value in screening for these
cancers.
We here report results on measurements of IGF-1, IGF-2, and
IGFBP-3 from the British United Provident Association (BUPA)
prospective study, based on 1051 new cases of cancer at 14
different cancer sites, and we combine the results on prostate,
colorectal, and lung cancer with those from published studies in a
meta-analysis.
METHODS
The BUPA study is a prospective study of 21 520 professional men
aged 35 –64 years resident in Britain who attended the BUPA
medical centre in London between 1975 and 1982 for a routine
medical examination. Serum samples were stored at 401C. The
men were flagged at the National Health Service Central Register in
Southport, permitting automatic notification of death (with the
certified cause) and cancer incidence by the Office for National
Statistics. Further information on the causes of death was obtained
by writing to each certifying doctor. This analysis is based on a
maximum follow-up of 15 years and is restricted to those cancers
for which at least 10 cases occurred. In this period, there were 1059
men for whom we had a cancer notification. For each case, three
controls (who were still alive and for whom we did not have a
cancer notification) were selected; they were matched for age and
duration of storage of the serum sample each to one year.
In 2003 the frozen serum samples were retrieved. The sample
was insufficient for eight cases; these and the corresponding
controls were excluded. The sample was also insufficient in 11
controls, leaving 1051 cases, 1040 cases with three controls and 11
cases with two controls, 3142 controls in total. IGF-1, IGF-2 and
IGFBP-3 were measured using DSL-10-5600 ACTIVE IGF-I, DSL-
10-9100 ACTIVE IGF-2 and DSL-10-6600 ACTIVE IGFBP-3
enzyme-linked ImmunoSorbent Assay (ELISA) kits. The serum
samples from the cancer cases and their matched controls were
systematically analysed together in the same analytical batch with
blinding so that the case was not identifiable. The samples from the
cases (and the corresponding controls) were analysed in groups
according to the type of cancer.
To determine if freezing the samples and storing them at 401C
affected the levels of IGF-1 and IGF-2, a separate set of samples was
analysed. Forty samples from the same BUPA cohort that the cases
and controls came from (collected between 1975 and 1982) were
randomly selected, five from each year of the study. Forty fresh
samples were obtained from men aged 35–64 years resident in
Britain who attended the BUPA medical centre in London in 2003.
The median levels from the samples prior to 1982 compared withReceived 24 February 2006; revised 2 May 2006; accepted 5 May 2006
*Correspondence: Dr JK Morris; E-mail: j.k.morris@qmul.ac.uk
British Journal of Cancer (2006) 95, 112 – 117
& 2006 Cancer Research UK All rights reserved 0007 – 0920/06 $30.00
www.bjcancer.com
E
p
id
e
m
io
lo
g
y
the median in 2003 were 1% (95% confidence interval (CI): 12%
to þ 25%) higher for IGF-1 (P¼ 0.66) and 6% (95% CI: 18% to
þ 4%) lower for IGF-2 (P¼ 0.93), indicating that storing the serum
at 401C for over 20 years did not reduce the levels of IGF-1 or
IGF-2.
The statistical analysis of the BUPA data was carried out as
follows: Pearson correlation coefficients were used to examine the
associations between IGF-1, IGF-2, IGFBP-3 and age within the
controls. The case–control matching was preserved for each
cancer site, rather than analysing the cases of a particular cancer
with all the controls. Conditional logistic regression models were
used to calculate odds ratios (OR) for cancer for quartile levels of
the markers, which takes account of the matching. Quartile cut
points were determined on the distribution of control subjects for
each cancer site separately. To determine if there was a significant
linear association with risk of cancer the original markers (that is
the continuous measurements not categorised into quartiles) were
entered into the conditional logistic regression model. Body mass
index (BMI), smoking and alcohol consumption were all
investigated as possible confounders for each cancer site
separately. BMI was analysed as a continuous measure. There
were seven smoking categories (nonsmokers, exsmokers, pipe and
cigar smokers and four categories of cigarette smokers (1–
15 day1, 15– 24 day1, 25–34 day1 and 35þ day1)) and five
alcohol categories (Teetotal, ‘Social’, 1– 2 units per day, 3–6 units
per day and 6þ units per day).
The meta-analysis was carried out as follows: We searched
MEDLINE and EMBASE from January 1996 to December 2005
combining the keywords IGF* and cancer to find published
prospective studies on IGF-1, IGF-2 and IGFBP-3 and cancer. We
searched citation lists from review articles and previously
published meta-analyses excluding breast and ovarian cancers, as
our data are only on men. Meta-analyses were performed on the
results using a random effects model for the published results from
prospective studies (using a nested case– control design). The odds
of cancer occurring in the top quartile of the marker compared
with the bottom quartile were combined. For studies that gave the
odds according to quintiles these were adjusted to quartile values.
For prostate, colorectal and lung cancers we included the results of
the present (BUPA) study in the meta-analysis. To assess for
publication bias, we examined the funnel plots for each cancer site
and tested if the regression of study estimate with study precision
was significant. We investigated all sources of heterogeneity with
subgroup analyses and also investigated the effects of adjusting
IGF-1 for IGFBP-3 levels and IGFBP-3 for IGF-1 levels as is often
perormed. Potential sources of heterogeneity investigated were:
year of publication, type of sample, average time from sample
collection to cancer diagnoses and study location. There was no
evidence of publication bias for any of the cancer sites.
RESULTS
Table 1 gives details of the study population including the number
of men according to cancer site and the mean age of the men at the
time of entry into the BUPA study and gives the medians and
interquartile ranges for IGF-1, IGF-2 and IGFBP-3 according to
case–control status and, as has been observed in other studies,
IGF-1 and IGFBP-3 were moderately correlated (r¼ 0.5) and both
declined with age (r¼0.18 for IGF-1 and age and r¼0.12 for
IGFBP-3 and age). IGF-2 was less highly correlated with IGFBP-3
(r¼ 0.29) and age (r¼0.10).
Prostate, colorectal and lung cancer results from the BUPA
study
Table 2 shows the odds of cancer according to quartiles (fourths)
of IGF-1, IGF-2 and IGFBP-3 for prostate, colorectal and lung
cancer. There were no statistically significant associations between
any of the cancers and any of the serum markers but the wide
confidence did not exclude relative risks of up to 3.4.
Results of the meta-analysis
Table 3 and Figure 1 shows the meta-analysis of IGF-1, IGF-2 and
IGFBP-3 results from published prospective studies and the results
from the present study (there were no published studies on IGF-2
and lung cancer). This analysis includes all the studies in the
earlier analysis by Renehan et al (2004) together with eight others
(Lacey et al, 2001; Wakai et al, 2002; Nomura et al, 2003; Woodson
et al, 2003; Stattin et al, 2004; Chen et al, 2005; Meyer et al, 2005;
Platz et al, 2005). The meta-analysis was restricted to data from
prospective studies to minimise any effects of the cancer on the
measurements made.
Prostate cancer The risk of developing prostate cancer for men in
the top quartile of IGF-1 compared with the bottom quartile was
1.31 (95%CI: 1.03–1.67; Table 3). There was no significant
heterogeneity between studies (P¼ 0.21). There was no association
between the risk of prostate cancer and IGF-2 (OR¼ 0.72; 95% CI:
0.36– 1.44; Table 3) or IGFBP-3 levels (OR¼ 1.05; 95%CI: 0.82–
1.35; Table 3).
In the present study prostate-specific antigen (PSA) was also
measured on the 141 men who developed prostate cancer and their
controls at the same time as measuring IGF-1. The odds ratio of
prostate cancer in the highest quartile compared with the lowest
quartile was very high (OR¼ 31 95% CI: 10– 92), demonstrating by
comparison the modest association with IGF-1, in spite of it being
statistically significant.
Table 1 BUPA study: characteristics at the time of screening of men
who developed cancer within 15 years and controls who did not
Controls Cases
Number of men 3142 1051
Mean age (years) 52.4 52.4
Median IGF-1 (ng ml1) (25th-75th
centiles)
124 (90–160) 122 (88–164)
Median IGF-2 (ng ml1) (25th–75th
centiles)
636 (517–767) 639 (514–772)
Median IGFBP-3 (mg ml1) (25th-75th
centiles)
3.2 (2.7–3.8) 3.2 (2.6–3.8)
Median time till diagnosis in cases
(years)
9.7
Proportion cases diagnosed within 3
years
8%
Proportion cases diagnosed within 10
years
53%
Number of men by site of cancer
Prostate 423 141
Colon and rectum 440 147
Lung 498 167
Bladder 234 78
Lymphoma 166 56
Stomach 123 41
Oesophagus 123 41
Skin 123 41
Pancreas 114 38
Brain 113 38
Kidney 110 37
Leukaemia 102 34
Mouth and pharynx 39 13
Larynx 38 13
Other/Multicancer 496 166
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Colorectal cancer There was a positive association (OR¼ 1.37
95% CI: 1.05–1.78) with IGF-1 and no evidence of heterogeneity
between the studies (P¼ 0.68). There was also a positive
association (OR¼ 1.95 95%CI: 1.26– 3.00) with IGF-2 and again
no evidence of heterogeneity between the studies (P¼ 0.87). For
IGFBP-3 there was no significant association (OR¼ 0.98 (0.64–
1.51), however, there was significant heterogeneity between studies
(P¼ 0.02). None of the subgroup analyses explained the hetero-
geneity between the studies.
Lung cancer There was no indication of an association between
IGF-1 and lung cancer (OR¼ 1.02 (0.80 –1.31)) nor between
IGFBP-3 and lung cancer (OR¼ 0.98 (0.61– 1.58)). However, there
was significant heterogeneity between the studies for IGFBP-3
(P¼ 0.01). The study by Spitz et al (2002) differed from the other
studies in that the cohort was of men who were heavy smokers and
asbestos workers. Excluding this study from the analyses resulted
in an odds ratio¼ 0.84 (0.52 –1.35) with a reduction in the
heterogeneity (P¼ 0.07) and there was evidence that the study
differed significantly from all the other studies (P¼ 0.002).
BUPA study results on 11 other site-specific cancers
The results are presented according to tertile group (not quartile
groups) because of the smaller numbers (Table 4). Cancers of the
oesophagus, mouth and pharynx were significantly associated with
lower levels of IGF-1 and cancer of the lymphoma was significantly
associated with lower levels of IGF-2. There were no statistically
significant associations between the 11 cancer sites with IGFBP-3.
The three associations are likely to be spurious results due to
multiple significance testing. There were no significant results
when all cancers were considered together for any of the markers.
DISCUSSION
Our results show that none of the growth factors measured (IGF1,
IGF2 or IGFBP3) have any value in cancer screening in men. The
strength of the associations are too weak for them to have any
useful effect in distinguishing people who will and will not develop
cancer at any of the sites studied. Relative risks of about two
between the top and bottom quartile groups translate into a
sensitivity (or detection rate) of less than 10% for a 95% specificity
(5% false-positive rate) (Wald et al, 1999). In contrast, the
corresponding odds ratio for prostate cancer between the top and
bottom quartile groups of PSA measured in this study was 31,
corresponding to a sensitivity of over 30% for a 95% specificity,
high enough for a potential screening test (Wald et al, 1999).
Combining the growth factors with other markers into a screening
test is also unlikely to be worthwhile, as in order to obtain a
reasonable screening performance over 20 tests with relative risks
of about two would be required (Wald et al, 2005).
Results relating to three female cancers, breast, ovary and
endometrium, were not included in our meta-analyses as they were
discussed in a recent meta-analysis by Renehan et al (2004)
(breast) and two papers by Lukanova et al (2002, 2004) (ovary and
endometrium). Renehan et al (2004) reported a relative risk of
premenopausal breast cancer between the top and bottom quartile
of IGF-1 of 2.08 (1.37 –3.15), with no significant associations for
postmenopausal breast cancer. Lukanova et al (2002, 2004)
reported a nonsignificant positive association between IGF-1and
premenopausal ovarian cancer (RR¼ 1.90 (0.63 –5.75)) with no
other associations approaching statistical significance. The
strengths of the associations between these female cancers and
the growth factors measured are not higher than any observed in
our study. There are no data relating to cervix cancer, but given the
overall pattern of results it would be surprising if cervix cancer was
an exception. We therefore are confident that the general
conclusion that none of the growth factors measured (IGF1,
IGF2 or IGFBP3) have any value in cancer screening can be
extended to all the main cancers in men and women.
Our second conclusion is that one of the growth factors, IGF2,
may be of aetiological significance in colorectal cancer. This was
suggested by the results from the two previous studies and is now
clarified by the meta-analysis including our own results on this
growth factor. Statistically significant associations between IGF-1
and colorectal and prostate cancer may also be of aetiological
significance, but the evidence is weaker.
This is the first report of a cohort study on associations with
cancers in men other than prostate, colorectal and lung.
Considering the small numbers of cancers diagnosed and the
likely OR of around 1.5, this study has low power to detect
significant associations in the less common cancers, but none-
theless there were no positive associations between any of the
cancers and any of the markers. The value of this study is to enable
the data to be included in future meta-analyses needed to have the
statistical power to investigate possible associations. We restricted
the analysis of the BUPA data to 15 years of follow-up since in the
Table 2 BUPA study: odds of prostate, colorectal, and lung cancer according to quartiles of serum levels of IGF-1, IGF-2 and IGFBP-3 within the first 15
years of follow-up (follow-up being the time between sample collection and diagnosis)
Adjusted odds ratiosa
Quartile groups
Site of cancer Analyte 1 (ref) 2 3 4 (95% CI) P for trend
Prostate
IGF-1 1 0.96 0.61 1.37 (0.76–2.49) 0.62
IGF-2 1 1.18 1.49 1.47 (0.77–2.81) 0.19
IBFBP-3 1 1.09 0.84 1.40 (0.77–2.55) 0.42
Colorectal
IGF-1 1 1.20 1.39 1.10 (0.56–2.18) 0.65
IGF-2 1 1.70 1.84 1.59 (0.67–3.75) 0.40
IBFBP-3 1 0.90 1.06 0.72 (0.37–1.37) 0.46
Lung
IGF-1 1 1.00 1.23 1.21 (0.62–2.35) 0.45
IGF-2 1 1.21 1.22 0.82 (0.39–1.73) 0.61
IBFBP-3 1 0.90 1.39 1.70 (0.87–3.30) 0.06
aThe odds ratios were adjusted for age by matching and were also adjusted: smoking for lung cancer and smoking, alcohol and body mass index for colon and rectum.
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Table 3 Meta-analysis: prospective studies of IGF-1, IGF-2 and IGFBP-3 and cancer of the prostate, colon and rectum and lung, ordered by mean time till diagnosis
Study
No. of
cases
No. of
controls Gender
Sample
mediuma
Adjust-
mentsb
Mean time
till diagnosis
(years)
Odds ratio highest quartile vs lowest quartile (95% CI)
IGF-1 IGF-2 IGFBP-3
Prostate cancer
Platz et al (2005) 462 462 m Pl 2.2 1.37 (0.92–2.03) 1.62 (1.07–2.46)
Chen et al (2005) 174 175 m Pl 3.4 0.67 (0.37–1.25) 0.65 (0.34–1.20)
Stattin et al (2004) 281 560 m Pl b,s 4.8 1.67 (1.02–2.71) 1.30 (0.84–2.03)
Meyer et al (2005) 100 400 m Pl 6.8 1.34 (0.68–2.65) 0.67 (0.34–1.30) 0.72 (0.35–1.48)
Chan et al (1998) 152 152 m Pl s 7 2.41 (1.25–4.74) 0.97 (0.48–1.95) 1.07 (0.54–2.11)
Harman et al (2000) 72 127 m Ser 9.2 1.65 (0.71–3.86) 0.24 (0.10–0.59) 0.71 (0.30–1.66)
Woodson et al (2003) 100 400 m Ser b 9.6 1.00 (0.54–1.87) 0.71 (0.36–1.39)
Current study (BUPA) 141 423 m Ser 10.4 1.37 (0.76–2.49) 1.47 (0.77–2.81) 1.40 (0.77–2.55)
Lacey et al (2001) 30 60 m Ser 14 0.70 (0.2–2.3) 1.1 (0.3–3.8)
Total 1512 2759 5.4 1.31 (1.03–1.67) 0.72 (0.36–1.44) 1.05 (0.82–1.35)
Test for heterogeneity:
P¼ 0. 21
Test for heterogeneity:
P¼ 0. 01
Test for heterogeneity:
P¼ 0. 19
Colorectal cancer
Giovannucci et al (2000) 79 158 F Pl a,b 3c 1.21 (0.52–2.81) 0.53 (0.18–1.53)
Palmqvist et al (2002) 168 336 M&f Pl s,l 3.35 1.27 (0.65–2.47) 1.23 (0.68–2.22)
Kaaks et al (2000); Hunt et al (2002) 102 200 F Ser s,l 4.8 1.88 (0.72–4.91) 2.08 (0.85–5.06) 2.46 (1.09–5.57)
Probst-Hensch et al (2001) 135 661 M Ser a,b,s 6.1 1.52 (0.82–2.85) 2.09 (1.14–3.82) 1.72 (0.91–3.25)
Ma et al (1999) 193 318 M Pl a,b,s 9c 1.36 (0.72–2.55) 0.47 (0.23–0.95)
Current study (BUPA) 147 440 M Ser a,b,s 9.6 1.10 (0.56–2.18) 1.59 (0.67–3.76) 0.72 (0.37–1.37)
Nomura et al (2003) 282 282 M Ser a,b,s 11 1.50 (0.8–2.8) 0.80 (0.4–1.6)
Total 1106 2395 7.6 1.37 (1.05–1.78) 1.95 (1.26–3.00) 0.98 (0.64–1.51)
Test for heterogeneity:
P¼ 0.68
Test for heterogeneity:
P¼ 0.87
Test for heterogeneity:
P¼ 0.02
Lung cancer
London et al (2002) 230 740 M Ser s 4 0.73 (0.43–1.24) 0.56 (0.30–1.03)
Wakai et al (2002) 194 9351 M&f Ser s,b 5.2 1.17 (0.78–1.77) 0.67 (0.45–1.01)
Spitz et al (2002) 159 297 M&f Ser s 6c 1.11 (0.64–1.93) 1.67 (0.96–2.92)
Lukanova et al (2001) 93 186 F Ser b,s,l 6.4 0.79 (0.29–2.19) 0.90 (0.36–2.25)
Current study (BUPA) 167 498 M Ser s 9.0 1.21 (0.62–2.35) 1.70 (0.87–3.30)
Total 843 11072 5.9 1.02 (0.80–1.31) 0.98 (0.61–1.58)
Test for heterogeneity:
P¼ 0.64
Test for heterogeneity:
P¼ 0.01
aPl¼ plasma, Ser¼ serum. bAll studies matched for age of cases. Other variables matched for are: a (alcohol consumption); b (body mass index); s (cigarette smoking); l (time since last food consumption); g(insulin and glucose). cMean
time till diagnosis estimated from the papers.
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other studies the meta-analysis had similar maximum lengths of
follow up. The data were also available for a further seven years of
follow-up, but their inclusion did not materially alter the results.
The published studies in the meta-analysis presented the odds
for IGF-1 adjusted for IGFBP-3 values and the odds for IGFBP-3
adjusted for IGF-1. Our meta-analysis provides no evidence that
IGFBP-3 is associated with cancer and therefore there is no reason
to adjust IGF-1 values for IGFBP-3. Such an analysis yields similar
estimates of the OR obtained for IGF-1 alone, confirming that it is
of little or no value in increasing the strength of the association.
0.2 1 2 5
Odds ratio highest quartile vs lowest quartile (95% CI)
Odds ratio 
IGF-1 IGFBP-3
1.31 (1.00 – 1.71)
1.37 (1.05 – 1.78)
1.02 (0.90 – 1.31)
1.05 (0.82 – 1.35)
0.98 (0.64 – 1.51)
0.98 (0.61 – 1.58)
IGF-2
Odds ratio 
0.72 (0.36 – 1.44)
1.95 (1.26 – 3.00)
Prostate cancer
Platz, 2005
Chen, 2005
Stattin, 2004
Meyer, 2005
Chan, 1998
Harman, 2000
Woodson, 2003
Current study (BUPA)
Lacey, 2001
All studies
Colorectal cancer
Giovannucci, 2000
Palmqvist, 2001
Kaaks, 2000
Probst-Hensch, 2001
Ma, 1999
Current study (BUPA)
Nomura, 2003
All studies
Lung cancer
London, 2002
Wakai, 2002
Spitz, 2002
Lukanova, 2001
Current study (BUPA)
All studies
Author and publication year 
0.5 0.2 1 2 50.5
Odds ratio 
0.2 1 2 50.5
Figure 1 Prospective studies of IGF-1, IGF-2 and IGFBP-3 and prostate, colorectal and lung cancer. The studies are ordered (top down) by increasing
average time interval between blood collection and cancer diagnosis.
Table 4 BUPA study: odds of cancer by tertile group of IGF-1, IGF-2 and IGFBP-3 for 11 common sites occurring during the first 15 years of follow-up
(follow-up being the time between sample collection and diagnosis)
Odds ratios in tertile
groupsa
IGF-1 IGF-2 IGFBP-3
Site of cancer 1 2 3 (95% CI)
P for
trend 1 2 3 (95% CI)
P for
trend 1 2 3 (95% CI)
P for
trend
Bladder 1 1.09 1.09 (0.50–2.35) 0.83 1 0.79 0.90 (0.42–1.91) 0.73 1 1.22 1.08 (0.54–2.18) 0.83
Lymphoma 1 0.53 1.30 (0.59–2.86) 0.48 1 0.43 0.42 (0.18–0.99) 0.04 1 0.74 0.58 (0.24–1.42) 0.23
Stomach 1 0.64 0.73 (0.28–1.94) 0.50 1 1.07 2.06 (0.51–8.41) 0.30 1 1.17 0.99 (0.37–2.68) 0.97
Oesophagus 1 0.59 0.21 (0.07–0.66) 0.01 1 0.57 1.20 (0.39–3.74) 0.48 1 0.87 1.34 (0.47–3.79) 0.60
Skin 1 1.11 2.26 (0.84–6.12) 0.10 1 2.05 2.27 (0.67–7.62) 0.15 1 2.09 1.90 (0.69–5.25) 0.22
Pancreas 1 0.50 0.68 (0.23–1.99) 0.48 1 0.63 0.48 (0.14–1.68) 0.24 1 0.62 0.74 (0.26–2.12) 0.59
Brain 1 1.13 1.18 (0.40–3.47) 0.77 1 0.56 1.06 (0.41–2.77) 0.90 1 0.48 0.44 (0.15–1.31) 0.12
Kidney 1 1.65 2.45 (0.85–7.07) 0.09 1 0.59 0.97 (0.26–3.62) 0.91 1 1.55 1.89 (0.66–5.48) 0.24
Leukaemia 1 0.57 1.20 (0.45–3.23) 0.75 1 1.02 0.50 (0.15–1.66) 0.25 1 1.18 0.61 (0.20–1.92) 0.37
Mouth and pharynx 1 0.25 0.10 (0.01–1.14) 0.05 1 1.36 1.20 (0.23–6.30) 0.83 1 0.24 0.33 (0.05–2.14) 0.19
Larynxb 1 0.23 1.09 (0.16–7.40) 0.92 — — — — 1 19.99 5.33 (0.09–315.99) 0.82
Other/Multicancer 1 0.84 0.89 (0.54–1.46) 0.65 1 1.00 0.86 (0.50–1.49) 0.61 1 0.80 0.89 (0.55-1.44) 0.64
Total (incl prostate,
colorectal and lung)
1 0.90 1.03 (0.84–1.27) 0.77 1 0.90 0.91 (0.71–1.15) 0.44 1 0.94 1.02 (0.83–1.25) 0.87
aThe odds ratios were adjusted for age by matching and were also adjusted for the following confounding factors in the statistical analysis according to site : smoking (pancreas,
larynx, mouth), alcohol (mouth, oesophagus) and body mass index (oesophagus, stomach). bThe odds ratios could not be calculated for IGF-2 and cancer of the larynx due to the
lack of heterogeneity of IGF-2 values amongst cases and controls.
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